Loading organizations...
UCL Technology Fund (UCLTF) is an early-stage investment vehicle commercializing intellectual property from University College London's research. It provides capital and expertise to founders in Physical and Life Sciences, transforming academic breakthroughs into scalable ventures. The fund supports development and market entry for new university technologies.
Established in 2016, UCLTF is a collaboration of University College London and Albion Capital, managed by AlbionVC and UCL Business (UCLB). This initiative arose from the insight that UCL's research offered commercialization opportunities, requiring a structure to transition innovations from academia to industry.
UCLTF primarily serves innovators and spin-out companies emerging from UCL’s research base. Its vision empowers these ventures to achieve global scale and deploy their intellectual property. The fund commits to maximizing the long-term societal and economic impact of UCL’s scientific discoveries.
London Technology Fund has 1 tracked investment across 1 company. The latest tracked deal is $13.0M Series A in Immune Targeting Systems in March 2010.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 1, 2010 | Immune Targeting Systems | $13.0M Series A | — | Earlybird Venture Capital, HealthCap, Novartis, Truffle Capital |